Skip to main content

Incannex Healthcare Limited (IXHL)

Incannex Healthcare will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Market Capn/a
Revenue (ttm)1.37M
Net Income (ttm)-3.55M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About IXHL

Since 2019, Incannex Healthcare has been conducting research and development for synthetic cannabidiol pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. Our mission is to create first-in-class pharmaceutical drugs and therapies for patients that we believe have unmet medical needs. In particular, we are developing three unique pharmaceutical compositions to target five indications: obstructive sleep apnea, traumatic brain injury/concussion, rheumatoid arthritis, inflammatory bowel disease and in...

IndustryPharmaceutical Preparations
IPO DatePending
CEOJoel Latham
Employees4
Stock ExchangeNASDAQ
Ticker SymbolIXHL
Full Company Profile

Financial Performance

Financial numbers in millions AUDFinancial Statements

News

Incannex Healthcare (ASX:IHL) files registration statement for proposed IPO in US

Incannex Healthcare (ASX:IHL) has filed a registration statement with the United States' Securities and Exchange Commission in relation to a proposed US public offering (IPO).

1 month ago - The Market Herald

Incannex Healthcare IPO Registration Document (S-1)

Incannex Healthcare Limited has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC